Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Preferred Stock Liabilities (2019 - 2020)

Nurix Therapeutics (NRIX) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $168.1 million as the latest value for Q2 2020.

  • On a quarterly basis, Preferred Stock Liabilities rose 248.81% to $168.1 million in Q2 2020 year-over-year; TTM through May 2020 was $168.1 million, a 248.81% increase, with the full-year FY2019 number at $48.2 million, changed N/A from a year prior.
  • Preferred Stock Liabilities was $168.1 million for Q2 2020 at Nurix Therapeutics, up from $48.2 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $168.1 million in Q2 2020 to a low of $48.2 million in Q2 2019.